MDM2 and melanoma: The combination of p53-activating agents, particularly inhibitors of the p53 interaction with MDM2 (e.g., nutlin-3a), with BRAF and MEK inhibitors, might therefore represent an appealing therapeutic strategy, potentially overcoming therapeutic resistance and improving disease-free survival of melanoma patients [7,18].